The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:1197-1198 March 13, 2008 Number 11
NextNext

Addition of Insulin to Oral Therapy in Type 2 Diabetes

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by McMahon, G. T.
-Related Article
by Holman, R. R.
-PubMed Citation
To the Editor: Holman et al. (Oct. 25 issue)1 report on the Treating to Target in Type 2 Diabetes (4-T) study of the addition of insulin to oral therapy in patients with type 2 diabetes. I think it is unreasonable for the authors to conclude that better glycemic control can be obtained with the addition of biphasic or prandial insulin than with the addition of basal insulin alone. Such a conclusion should be drawn only from trials with equal "insulinization" of the study groups. Since insulin detemir has a lower affinity, the mean daily molar dose requirement for basal insulin . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.